As a severe flu season continues to unfold in the U.S., GlaxoSmithKline is touting phase 3 study data showing its Fluarix Tetra can protect young children who are among the most vulnerable to the virus.Original Article
GlaxoSmithKline’s Fluarix protects young children in large phase 3 test
